Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

Abstract Background Chemotherapy-induced ovarian failure (CIOF) is a frequent side-effect of adjuvant chemotherapy that results in rapid bone loss. We hypothesised that zoledronic acid (ZA), a third-generation amino bisphosphonate, would prevent bone loss in premenopausal women who developed CIOF. Methods Women (439) were randomised to intravenous (i.v.) ZA 4 mg every 3 months for 2 years starting within 1–3 months after randomization (arm A) or 1 year after randomization (arm B, controls). CIOF was prospectively defined as ⩾3 months of amenorrhoea, follicle-stimulating hormone (FSH) ⩾30 MIU/ml and non-pregnant at 1 year. The primary end-point was the percentage change in bone mineral density (BMD) in the lumbar spine (LS) from baseline to 12 months in the ZA and in control groups in women who developed CIOF; the secondary end-point was BMD in LS at 3 years in all randomised women. Findings One hundred and fifty (56%) met the definition of CIOF at 1 year. Overall, grade 3 toxicities of ZA were fatigue (1%) arthralgias (21%) and pain (84%). The median percent change (interquartile range, IQR) at 1 year was +1.2% (−0.5% to +2.8%) and −6.7% (−9.7% to −2.9%) p < 0.001 and at 3 years was +1.0% (−1.6% to +5.2%) and −0.5% (−3.7% to +3.2%) p = 0.019 in arms A and B, respectively. Interpretation ZA every 3 months is well tolerated and prevents rapid bone loss in premenopausal women that develop CIOF. Giving ZA with rather than 1 year after the start of adjuvant chemotherapy is the preferred sequence to prevent bone loss.